Clinical trials: Meridian
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
- Trial name
- NCT04579666
- Testing
- Pegcetacoplan (APL-2)
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 249 people
- Sponsor
- Apellis Pharmaceuticals, Inc.